STERIS plc Form 10-K Summary
Reporting period: Fiscal year ended March 31, 2023. Although the request references 2022 Q4, this filing is an annual Form 10-K and does not provide a clear standalone fourth-quarter income statement.
Business context
STERIS provides infection-prevention products and services across four segments: Healthcare, Applied Sterilization Technologies (AST), Life Sciences, and Dental. Offerings include capital equipment, consumables, maintenance, instrument and endoscope repair, outsourced reprocessing, contract sterilization, laboratory testing, and dental instruments.
Key financial metrics
| Metric | FY2023 | FY2022 | Change |
|---|---|---|---|
| Revenue | $4,957.8 million | $4,585.1 million | 8.1% increase |
| Gross profit | $2,159.7 million | $2,016.4 million | 7.1% increase |
| Gross margin | 43.6% | 44.0% | 40 basis-point decline |
| Operating income | $268.2 million | $425.6 million | 37.0% decrease |
| Net income attributable to shareholders | $107.0 million | $243.9 million | 56.1% decrease |
| Diluted EPS | $1.07 | $2.48 | 56.9% decrease |
| Cash flow from operations | $756.9 million | $684.8 million | 10.5% increase |
| Free cash flow | $409.6 million | $399.0 million | 2.7% increase |
Revenue growth reflected higher volume, pricing, a full year of Cantel activity, and growth across all segments, partially offset by foreign-exchange effects and divestitures. Capital equipment revenue increased 12.8%, service revenue increased 7.1%, and consumable revenue increased 6.7%.
The principal earnings distortion was a $490.6 million non-cash goodwill impairment charge related to the Dental segment. Excluding this item, reported operating performance was stronger, but the filing does not present a single adjusted operating-income or adjusted EPS figure in the provided text.
Segment performance
| Segment | FY2023 revenue | Revenue change | FY2023 operating margin |
|---|---|---|---|
| Healthcare | $3,085.1 million | 8.4% increase | 22.9% |
| AST | $914.4 million | 7.2% increase | 46.9% |
| Life Sciences | $536.7 million | 2.2% increase | 39.2% |
| Dental | $421.6 million | 16.6% increase, largely due to acquisition timing | 21.2% |
Healthcare operating margin improved modestly, while AST, Life Sciences, and Dental margins declined because of labor, energy, supply-chain, inflation, and productivity pressures.
Liquidity, cash flow, and debt
- Cash and cash equivalents were $208.4 million at March 31, 2023, compared with $348.3 million at March 31, 2022.
- Capital expenditures were $362.0 million, up from $287.6 million, driven primarily by additional AST investment.
- Total debt was $3.079 billion at March 31, 2023, compared with $3.088 billion at March 31, 2022.
- Debt-to-total-capital increased to 33.6% from 32.1%.
- The company had $938.4 million of unused revolving-credit capacity, after $301.7 million of borrowings and $9.9 million of letters of credit.
- Debt maturities totaled $60.0 million in fiscal 2024, $165.9 million in fiscal 2025, $479.2 million in fiscal 2026, and $614.9 million in fiscal 2027.
- Interest expense increased to $108.0 million from $89.6 million, primarily because of higher rates on floating-rate debt. A hypothetical 100-basis-point increase in floating rates would increase annual interest expense by approximately $10.0 million.
- Cash dividends paid were $183.5 million, or $1.84 per share. The quarterly dividend was increased to $0.47 per share.
- STERIS repurchased 1.56 million shares for $295.0 million during fiscal 2023. On May 3, 2023, it authorized a new $500.0 million repurchase program.
Material changes versus the prior comparable period
- Revenue increased 8.1%, but operating income and net income declined substantially because of the Dental goodwill impairment and higher amortization.
- Gross margin contracted by 40 basis points; inflation reduced margin by approximately 330 basis points and productivity reduced it by approximately 50 basis points, partly offset by pricing, mix, divestitures, and currency.
- Operating cash flow increased by $72.1 million, while free cash flow increased only $10.6 million because of higher capital spending and working-capital investment.
- Accounts receivable increased to $928.3 million from $799.0 million, and inventories increased to $695.5 million from $575.0 million.
- SG&A declined 13.6%, primarily because Cantel acquisition and integration costs and incentive compensation were lower.
- Fiscal 2023 included approximately $49.8 million of tuck-in acquisitions. STERIS also sold certain Animal Health assets, recognizing a pre-tax loss of approximately $4.9 million.
- Backlog increased to $599.6 million from $528.3 million at March 31, 2022, excluding Cantel from the prior-year comparison.
Guidance, outlook, risks, and unusual items
Management expects to manage costs, develop products and services internally, invest in capacity, and pursue potential acquisitions. It anticipates continued supply-chain and inflation pressures in fiscal 2024 and plans further facility expansion, particularly in Healthcare and AST.
- Raw-material, energy, labor, and logistics costs remain significant risks. Key AST inputs, including ethylene oxide and cobalt-60, have limited or single-source availability in some regions.
- STERIS stopped purchasing cobalt-60 from its Russian supplier and ceased commercial operations in Russia and Belarus. Management does not currently expect a material AST impact, but a prolonged disruption could affect gamma-processing capacity or costs.
- Regulatory and litigation exposure is significant, particularly relating to medical devices, environmental compliance, ethylene oxide sterilization, product liability, and recalls.
- Dental revenue concentration is notable: three customers collectively represented approximately 47.4% of Dental segment revenue.
- The company carries substantial goodwill and intangible assets. Goodwill was $3.879 billion and net intangible assets were $2.956 billion at March 31, 2023. Further impairment charges remain possible if operating or market assumptions deteriorate.
- The company disclosed two IRS proposed adjustments concerning fiscal 2018 deemed dividend inclusions and withholding tax, which could result in approximately $50 million of cumulative tax liability. No reserve was recorded because management believes its position is more likely than not to be sustained.
- Legal proceedings and contingencies are considered adequately reserved and not expected to be material in aggregate, but outcomes remain inherently uncertain.
- Ernst & Young issued unqualified opinions on the financial statements and internal control over financial reporting. The audit identified uncertain tax positions and Dental goodwill impairment as critical audit matters.
Investor verification checklist
- Verify the impact of the $490.6 million Dental goodwill impairment on normalized earnings and future Dental profitability.
- Assess whether pricing actions can offset continuing inflation, labor, energy, and supply-chain costs without further margin erosion.
- Review debt maturity schedules, floating-rate exposure, covenant compliance, credit ratings, and the refinancing requirements for 2025 through 2027.
- Monitor working-capital trends, particularly the growth in inventories and accounts receivable relative to revenue.
- Evaluate AST exposure to ethylene oxide regulation, cobalt-60 availability, environmental claims, and related litigation.
- Assess customer concentration in Dental and the potential effect of distributor purchasing patterns or customer loss.
- Review the IRS tax matter and evolving U.S., Irish, EU, OECD Pillar Two, and other international tax rules.
- Reconcile reported results with non-GAAP measures used by management and confirm the effect of Cantel acquisition timing and other portfolio actions on period comparability.